▎WuXiEdited by Kant Content Team

Recently, Eli Lilly and Company announced the detailed results of the three-year SURMOUNT-1 Phase 3 clinical study.Published in The New England Journal of Medicine (NEJM) Above. The published research results show that, compared with the placebo,Weekly injections of tirzepatide can significantly reduce the risk of developing type 2 diabetes by 93% in adults with prediabetes and obesity or overweight.

SURMOUNT-1It is a multi-center, randomized, double-blind, placebo-controlled3Phase clinical trial, aimed at evaluating different doses (5 mg、10 mgAnd15 mg) oftirzepatideEfficacy and Safety as an Adjunctive Treatment to Low-Calorie Diet.The analysis results released this time include1032Obese or overweight adults with prediabetes, who were randomly assigned to receive a placebo or different dosestirzepatideThe treatment, with a treatment period of176Week, Continuation17Weeks of discontinuation period (totaling193Week).

Published inNEJMThe results show,At week 176, those receiving 5 mg, 10 mg、15 mg The average percentage change in body weight for subjects treated with tirzepatide versus placebo was -12.3%, -18.7%, -19.7%, and -1.3%, respectively.(Compared with the placebo group, P-values for all comparisons<0.001）。The number of subjects diagnosed with type 2 diabetes in the Tirzepatide group was fewer than in the placebo group.，Weekly injection of tirzepatideCompared with placeboCan significantly reduce the risk of patients developing type 2 diabetes by 93%.(1.3% vs. 13.3%; HR=0.07; 95% CI: 0.0 to 0.1; P<0.001）。Seventeen weeks after discontinuation of treatment or placebo, 2.4% of participants who received tirzepatide had type 2 diabetes, compared with 13.7% in the placebo group (HR=0.12; 95% CI: 0.1 to 0.2; P<0.001).

▲Summary of Efficacy Results from the SURMOUNT-1 Trial (Image Source: Reference [1])

In terms of other endpoints, the study showedtirzepatideTreatment is associated with improvements in glycemic control, cardiometabolic disease risk factors (including fasting insulin, blood pressure, and lipid profile), and health-related quality of life, and these improvements are...176Persistent throughout the week.Post-analysis shows that,About half of the effect of tirzepatide in delaying the onset of type 2 diabetes is associated with drug-induced weight loss, while the remaining benefits may be attributed to other actions of tirzepatide.

The overall safety and tolerability profile of tirzepatide over 193 weeks (176 weeks of treatment plus 17 weeks of non-treatment) was consistent with the results at 72 weeks from prior trials and with findings from other tirzepatide clinical studies.

Tirzepatide is a dual GIP/GLP-1 receptor agonist that can simultaneously activate signaling pathways mediated by both GLP-1 and GIP receptors.GIPAndGLP-1It is a natural incretin hormone that regulates blood sugar.TirzepatideIn2022Year5Month Obtained in the United StatesFDAApproval (Trade Name:Mounjaro), used in conjunction with controlled diet and exercise to improve conditions in adults2Blood glucose control in patients with type diabetes.Last year11Month,tirzepatideReacquireFDAApproval (Trade Name:Zepbound), used to help obese or overweight adult patients lose weight and maintain a stable weight.According to the press release,tirzepatideIs the first approvedGIP/GLP-1Receptor Dual Agonist.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks. Retrieved November 14, 2024 from https://investor.lilly.com/news-releases/news-release-details/treatment-tirzepatide-adults-pre-diabetes-and-obesity-or

[2] Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819. Epub ahead of print. PMID: 39536238.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规医院.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.